Philip Thompson, MBBS (Hons)

Consultant Haematologist
Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre and The Sir Peter MaCallum Department of Clinical Oncology, University of Melbourne, Australia

N/A

Poster(s):

• 1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244

• 1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study

• 1150 - Past informs the future: outcomes post allogeneic stem cell transplantation in high risk chronic lymphocytic leukaemia (CLL)

• 1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon

• 3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)